Alphabet Inc.

Institutional investor · Portfolio as of Q1 2022

Top Holdings60 positions

Checking export access…
Activity:
DXCM

DexCom, Inc.

1.1M$537.5M17.4%$77.24+65.58%
11 qtrssince 2019-Q3
Increased
84
PATH

UiPath, Inc.

14.1M$303.7M9.9%$67.93-68.22%
4 qtrssince 2021-Q2
Unchanged
0
IONQ

IonQ, Inc.

21.9M$279.5M9.1%$16.70-73.77%
2 qtrssince 2021-Q4
Unchanged
0
VERV
VERVDelisted

VERVE THERAPEUTICS INC

11M$250.4M8.1%——
4 qtrssince 2021-Q2
Unchanged
0
OSCR

Oscar Health, Inc.

24M$239.7M7.8%$26.88-62.91%
5 qtrssince 2021-Q1
Unchanged
0
LYFT

Lyft, Inc.

6.1M$235.7M7.6%$40.84-5.97%
11 qtrssince 2019-Q3
Unchanged
0
EQRX
EQRXDelisted

EQRX Inc

47.6M$196.4M6.4%——
2 qtrssince 2021-Q4
Unchanged
0
PL

Planet Labs PBC

31.9M$162.3M5.3%$6.15-17.40%
2 qtrssince 2021-Q4
Unchanged
0
SNOW

Snowflake Inc.

535,604$122.7M4.0%$229.130.00%
1 qtr
New
83
RCUS

Arcus Biosciences, Inc.

2.6M$80.9M2.6%$9.10+178.46%
11 qtrssince 2019-Q3
Unchanged
0
FRSH

Freshworks Inc.

4M$72.3M2.3%$26.26-31.76%
2 qtrssince 2021-Q4
Unchanged
0
HOOD

Robinhood Markets, Inc.

4.9M$66.6M2.2%$42.08-67.89%
3 qtrssince 2021-Q3
Unchanged
0
DM
DMDelisted

Desktop Metal Inc

11M$52.4M1.7%——
6 qtrssince 2020-Q4
Unchanged
0
BHIL
BHILDelisted

Benson Hill Inc

15.4M$49.6M1.6%——
3 qtrssince 2021-Q3
Increased
48
RLAY

Relay Therapeutics, Inc.

1.6M$47M1.5%$41.71-28.24%
7 qtrssince 2020-Q3
Increased
46
TOST

Toast, Inc.

1.4M$31.1M1.0%$34.71-37.40%
2 qtrssince 2021-Q4
Decreased
0
LYEL

Lyell Immunopharma, Inc.

5.9M$29.6M1.0%$324.80-68.90%
4 qtrssince 2021-Q2
Unchanged
0
IVVD

Invivyd, Inc.

5.7M$25.9M0.8%$42.24-89.20%
3 qtrssince 2021-Q3
Unchanged
0
ME
MEDelisted

23ANDME HOLDING CO

6.7M$25.8M0.8%——
2 qtrssince 2021-Q4
Unchanged
0
SANA

Sana Biotechnology, Inc.

2.8M$23.2M0.8%$33.47-75.32%
5 qtrssince 2021-Q1
Unchanged
0
$3.1B
AUM
60
Positions
Q1 2022
Filing
HI rating · 2.5/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2020-Q4$2,084,295,000-2.0907064161%
2021-Q1$2,480,501,00019.0091133933%
2021-Q2$4,908,269,00097.8740988212%
2021-Q3$4,215,098,000-14.1225144751%
2021-Q4$4,141,375,000-1.74902220541%
2022-Q1$3,082,033,000-25.5794754158%
Activity profile
$ moved · Q1'22
New19%Increased32%Decreased49%Exited0%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 1.0 years
<1Q5%1-4Q53%1-2Y18%2Y+23%

Alphabet Inc. manages $3.1B across 60 positions as of Q1 2022. Top holdings: DXCM (17.4%), PATH (9.9%), IONQ (9.1%). Fund DNA: Concentrated Value. HoldingsIntel Score: 2.5/5.0.

Q1 2022 Summary

Added SNOW, RANI and HLTHQ; exited UBER; increased 3, led by DXCM (+346,584 shares); trimmed 6, led by TOST (−8.1M shares). Top move: DXCM (INCREASED, conviction 84). Portfolio: $3.1B across 60 positions.

Top holdings by portfolio weight

Total AUM$3B
DXCM17.44%
PATH9.86%
IONQ9.07%
VERV8.13%
OSCR7.78%
LYFT7.65%
EQRX6.37%
PL5.26%
SNOW3.98%
RCUS2.63%
Other2.35%

Portfolio allocation by GICS sector

Sectors6
Healthcare37.16%
Technology34.63%
Unknown20.69%
Industrials5.28%
Financial Services2.22%
Communication Services0.02%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Healthcare, Technology, Unknown
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Solid(2.5 / 5.0)
Holdings P&L42
Conviction73
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used